Ads
related to: cytarabine 7 3 regimen for aml- View Dosing Guidelines
Clinical Dosing Guidelines For
an AML Treatment Option.
- AML Treatment Option
See If an AML Treatment Option
May Be Able To Help Your Patients.
- Testing For AML
Learn About The Importance of
Testing For Mutations in AML.
- Clinical Recommendations
Info On a Treatment Recommendation
From An AML Treatment Guideline.
- Safety & Efficacy Info
View The Potential Adverse
Reactions For a Treatment Option.
- Learn About The MOA
Watch a Video That Explains
The Mechanism of Action.
- View Dosing Guidelines
Search results
Results From The WOW.Com Content Network
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
daunorubicin x 3 days plus ara-C x 7 days, a variant of 7+3 regimen Acute myeloid leukemia, excluding acute promyelocytic leukemia: DAT: daunorubicin, cytarabine (ara-C), tioguanine: Acute myeloid leukemia: DCEP dexamethasone, cyclophosphamide, etoposide, platinum agent: relapsed or refractory multiple myeloma DHAP
Cytarabine, also known as cytosine arabinoside (ara-C), is a chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma. [2] It is given by injection into a vein, under the skin, or into the cerebrospinal fluid. [2]
AMML can be treated depending on the degree of disease, age of patient, and current patient's health status. Treatment consists of a multi-drug chemotherapy regimen. [11] Chemotherapy drugs often used to treat AML are cytarabine and an anthracycline drug. Chemotherapy is broken down into 2 phases:
This induction chemotherapy regimen is known as "7+3" (or "3+7"), because the cytarabine is given as a continuous IV infusion for seven consecutive days while the anthracycline is given for three consecutive days as an IV push. [62]
HDAC is also used as a consolidation regimen in acute myeloid leukemia after initial 7+3 induction. HDAC also can be used as the primary induction therapy in AML, with higher than in 7+3 success (remission) rate, but it is more toxic and causes more treatment-related complications and treatment-related mortality than 7+3 when used as primary ...
Ads
related to: cytarabine 7 3 regimen for aml